Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| HROW | PRESS-RELEASE | bearish | 8/10 | No summary provided | Aug 10, 2026 |
| PROK | PRESS-RELEASE | neutral | 5/10 | ProKidney reported Q2 2026 financial results with no revenue or EPS guidance to analyze, as the company is pre-commercia | Aug 10, 2026 |
| DMRA | PRESS-RELEASE | bearish | 7/10 | Damora Therapeutics reported Q2 2026 EPS of -$0.62, a 67.6% miss versus consensus of -$0.37, driven by sharply higher R& | Aug 10, 2026 |
| VERA | PRESS-RELEASE | mixed | 7/10 | Vera Therapeutics reported Q2 2026 net loss of $109.5M (-$1.52 EPS), wider than the $76.5M loss in Q2 2025 and a miss vs | Aug 10, 2026 |
| SANA | PRESS-RELEASE | neutral | 4/10 | Sana Biotechnology reported Q2 2026 GAAP net loss of $63.6M ($0.22/share), slightly narrower than the year-ago $93.8M lo | Aug 10, 2026 |
| SEPN | 8-K | neutral | 4/10 | Septerna reported Q2 2026 financial results with a net loss of $13.0M, narrower than the $24.8M loss in Q2 2025. Revenue | Aug 10, 2026 |
| BBIO | 8-K | neutral | 5/10 | BridgeBio reported Q2 2026 revenue of $243.7M, more than doubling YoY, driven by $222.4M in Attruby sales. The company c | Aug 10, 2026 |
| OLMA | PRESS-RELEASE | neutral | 4/10 | Olema Oncology's Q2 2026 net loss widened to $63.2M (vs $43.8M a year ago) on higher R&D and G&A spending, but cash of $ | Aug 10, 2026 |
| BBIO | PRESS-RELEASE | mixed | 6/10 | BridgeBio reported Q2 2026 total revenues of $243.7M (+120.5% YoY), driven by $222.4M in Attruby net product revenue (+2 | Aug 10, 2026 |
| SEPN | PRESS-RELEASE | neutral | 4/10 | Septerna reported Q2 2026 financial results highlighting a net loss of $13.0M (EPS -$0.29) vs consensus of -$0.48, a 39. | Aug 10, 2026 |
| AMRX | 8-K | mixed | 7/10 | Amneal completed its acquisition of Kashiv BioSciences on August 10, 2026, paying $375M in cash and issuing 28,942,098 s | Aug 10, 2026 |
| PRTA | INSIDER-BUY | bullish | 5/10 | William P. Scully, a 10% owner of Prothena, made a single-day open-market purchase of 37,500 shares for $323K on August | Aug 10, 2026 |
| CMPS | 144 | neutral | 3/10 | Former director Annalisa Jenkins filed a Form 144 notice of intent to sell 26,000 American Depositary Shares of COMPASS | Aug 10, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's terminated a distribution and promotion agreement with Novartis India Limited (NIL) due to a change in NIL's | Aug 10, 2026 |
| GRTX | EFFECT | bearish | 6/10 | Galera Therapeutics, Inc.'s registration statement on Form POS AM (File No. 333-251061) was declared effective by the SE | Aug 10, 2026 |
| VRXA | EFFECT | bearish | 6/10 | Veraxa Biotech's F-1 registration statement (File No. 333-297907) became effective on August 6, 2026, enabling the resal | Aug 10, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K with an exhibit for an application to quote securities (ATH) on the Australian Se | Aug 10, 2026 |
| IPHA | 6-K | neutral | 3/10 | Innate Pharma announced the appointment of Markus Jensen as Chief Medical Officer, effective June 1, 2026, succeeding So | Aug 10, 2026 |
| ATAI | DEFM14A | bullish | 7/10 | AtaiBeckley shareholders are asked to vote on the acquisition by Eli Lilly for $6.75 per share in cash plus one CVR per | Aug 10, 2026 |
| SLXN | 8-K | neutral | 5/10 | Silexion Therapeutics published an updated corporate presentation on August 10, 2026, detailing its lead product candida | Aug 10, 2026 |
| AIM | PRESS-RELEASE | bearish | 5/10 | AIM ImmunoTech reported Q2 2026 net loss of $(3.8M) or $(0.43) per share, a 258% miss vs consensus of $(0.12). The compa | Aug 10, 2026 |
| HRTX | PRESS-RELEASE | bearish | 7/10 | Heron Therapeutics reported Q2 2026 revenue of $37.7M (missed consensus of $42.2M by 10.7%) and GAAP EPS of -$0.03 (miss | Aug 10, 2026 |
| COGT | PRESS-RELEASE | neutral | 5/10 | Cogent Biosciences reported Q2 2026 net loss of $96.4 million (EPS $-0.60 vs consensus $-0.56, a 6.2% miss) as R&D and G | Aug 10, 2026 |
| NTHI | PRESS-RELEASE | mixed | 6/10 | NeOnc reported Q2 2026 EPS of -$0.58, well below the -$0.16 consensus, with net loss widening to $14.2M on higher R&D sp | Aug 10, 2026 |
| QNTM | 6-K | bullish | 8/10 | Quantum BioPharma announced FDA clearance of its IND application for Lucid-MS, a first-in-class neuroprotective candidat | Aug 10, 2026 |
| AQST | 8-K | bullish | 7/10 | Aquestive Therapeutics announced positive topline results from its human factors validation and pharmacokinetic studies | Aug 10, 2026 |
| SION | 8-K | bearish | 7/10 | Sionna Therapeutics announced that its Phase 2a PreciSION CF trial of SION-719 failed to meet its key activity endpoint | Aug 10, 2026 |
| TENX | 8-K | mixed | 7/10 | Tenax Therapeutics (TENX) announced that its Phase 3 LEVEL trial of TNX-103 for PH-HFpEF failed to meet the primary endp | Aug 10, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine 6-K disclosing the vesting of restricted shares under its '100th Anniversary Shares' progra | Aug 10, 2026 |
| NVO | 6-K | neutral | 2/10 | Novo Nordisk filed a routine weekly update on its ongoing DKK 15 billion share repurchase program, reporting B share rep | Aug 10, 2026 |